Publications   Surgery Photos   No-Scalpel Vasectomy   Impotence   Laparoscopic Surgery   Dr. Whang's Blog   Transplant experience  

Date : 14-01-17 00:40     
Writer : HIFU    Views : 31,512
Tool may predict prostate Ca over diagnosis risk
Dr. Whang Comments :
This article talks of a nomogram that can tell whether a patient found with prostate cancer has been “over diagnosed”.  It is interesting for people to say someone is over diagnosed but to the patient, he is not over diagnosed.  He is 100 % diagnosed.  We in medical community need to be more careful about this kind of statement.  We should be using all tools including active surveillance, surgery, HIFU, Cryo, Radiation therapy, hormonal therapy judiciously to treat our patients who are diagnosed with prostate cancer. 

Tool may predict prostate Ca over diagnosis risk 
Publish date: JAN 13, 2014 

By: Richard R. Kerr
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington in Seattle have developed a personalized tool that they say can predict the likelihood of prostate cancer over diagnosis.
The researchers created a nomogram that incorporates a patient’s age, PSA level, and Gleason score to determine the likelihood that screening-detected prostate cancer has been over diagnosed.
The goal, said Roman Gulati, the study’s lead author, is to provide patients and clinicians with a tool that can help them better determine personalized treatment options.
“Men with screen-detected prostate cancer are making decisions about treatment based on limited information about the chances that their cancer has been over diagnosed,” said Gulati, of Fred Hutchinson Cancer Research Center. “We think this is a useful tool for patients and their providers because it helps to tailor knowledge of the risks and benefits of different treatment choices to their individual situations.”
To develop the nomogram, the researchers created a virtual population model representing U.S. men aged 50 to 84 years from 1975 to 2005 and applied existing data on PSA levels, biopsy practices, and cancer diagnosis patterns to learn about cancer progression in patients with and without screening. The researchers then overlaid screening and biopsy patterns on the model to determine when the men would have been diagnosed with and without screening, and which would have died of other causes.
They developed a prediction model, which estimates that the likelihood of over diagnosis ranges from 2.9% to 88.1% depending on patient age, PSA level, and Gleason score at diagnosis, as reported online in the Journal of the National Cancer Institute (Jan. 7, 2014).
While prostate cancer nomograms are not new, the current one is the first to determine the likelihood of over diagnosis on an individual level, said Ruth Etzioni, PhD, the paper’s senior author.
“We’re trying to help patients who are the most likely to be over diagnosed to recognize it and not be afraid to be more conservative in their treatment,” Dr. Etzioni said.
“This nomogram will provide clinically relevant information for both the provider and patient on which to base practical decision-making for newly diagnosed prostate cancer,” added Daniel Lin, MD, a University of Washington urologist. “We fully realize that many men do not need immediate treatment for their cancer and can be safely placed on an active surveillance protocol, and this important research will further clarify those who may avoid treatment versus those men who may benefit from attempted curative therapy.”


Contact us | HOME |  matthew whang facebook  matthew whang youtube  matthew whang twitter 
ABOUT HIFU About HIFU |  Contact us |  Treatments |  Considering HIFU? |  FAQ |  Privacy Statement |  CURRICULUM VITAE |  HIFU VIDEO |  VIDEO | 
UROLOGY Publications |  Surgery Photos |  No-Scalpel Vasectomy |  Impotence |  Laparoscopic Surgery |  Dr. Whang's Blog |  Transplant experience | 
Dr. Matthew Whang Urology Group of New Jersey | 1001 Pleasant Valley Way, West Orange, NJ 07052 | Tel.: ( 973) 669-8448 I Fax: (973) 669- 9536
Copyright 2013. All right reserved. Dr. Matthew Whang